Lymphoma: this blood test could predict whether immunotherapy will work

Lymphoma: this blood test could predict whether immunotherapy will work
CAR-T therapies have revolutionized the treatment of certain aggressive lymphomas, but they do not work in all patients. American researchers have discovered that a genetic signature present in the blood could help anticipate their effectiveness.

Published on November 18, 2026 in Cell Reports Medicinea study led by Cornell and the Dana-Farber Cancer Institute shows that certain circulating RNA fragments are associated with a better chance of responding to treatment with CAR-T therapy. In 91 patients, this signature was linked to an 80% reduction in the risk of disease progression.

CAR-T: why do some patients respond better than others?

For people with relapsed or treatment-resistant large B-cell lymphoma, CAR-T therapies represent a major hope. Their principle: take the patient’s T lymphocytes, modify them genetically in the laboratory so that they recognize cancer cells, then reinject them into the body.

This personalized immunotherapy has profoundly changed the management of certain blood cancers. But it does not guarantee lasting remission. According to researchers, almost half of patients do not respond to treatment or experience a relapse within a year.

“CAR-T cell therapy is one of the great advances of recent decades, but not all patients respond to it.”explains Iwijn De Vlaminck, professor at Cornell University and leader of the study.

Why such a difference between patients? To try to answer, the researchers explored one avenue: searching the blood for clues allowing us to anticipate the effectiveness of the treatment even before its administration.

A blood test to observe the environment of the tumor

The effectiveness of CAR-T does not only depend on the characteristics of the cancer cells. It could also be influenced by their immediate environment, called the tumor microenvironment. This brings together immune cells, support cells and blood vessel cells, which can promote or slow down the action of the treatment.

A study published in 2025 in Cancer Cell had already identified three microenvironment profiles. Tumors presenting an environment close to that of a lymph node seemed in particular to respond better to CAR-T.

But this analysis requires tissue samples, including biopsies. The Cornell team therefore wanted to know if a simple blood test could provide comparable information.

The researchers were interested in circulating cell-free RNA, fragments of genetic material released into the blood by the body’s cells.

“RNA circulating in blood plasma could provide this signal, providing a window not only into the immune system, but also potentially into tissues.”explains Iwijn De Vlaminck. “The advantage is that we can take this sample non-invasively.”.

An 80% lower risk of progression in some patients

To test this hypothesis, scientists analyzed blood samples from 91 patients with large B-cell lymphoma, treated at the Dana-Farber Cancer Institute with axicabtagene ciloleucel, marketed under the name Yescarta. Their median age was 65 years.

Divided into three independent groups, the patients underwent analysis of their plasma RNA to look for a genetic signature associated with the lymph node microenvironment.

The results are encouraging: patients with a score above the median had an approximately 80% lower risk of disease progression than patients with a low score. This association with better progression-free survival was found in all three groups.

Patients who responded to treatment also had higher scores than non-responders.

The researchers also checked whether this signature simply reflected the quantity of cancer cells in the body. They did not find any significant correlation with LDH, a biological marker sometimes used to indirectly assess tumor mass.

These observations suggest that plasma could provide information on tissue activity and the tumor environment, beyond just the composition of blood cells.

Hope to personalize treatments, but validations necessary

Ultimately, this discovery could make it possible to identify patients whose tumor environment is less favorable before CAR-T administration. Doctors could then consider additional treatments to modify it, such as targeted radiotherapy or drugs acting on certain macrophages, immune cells involved in the tumor environment.

But caution remains essential. The study involves 91 patients, in a single American center, and concerns a particular CAR-T product. The results need to be confirmed in larger cohorts and across multiple institutions.

Glory Feyisayo Agun, first author of the study, recalls this necessity in the Cornell Chronicle : “The next step would be to extend this work to other patients receiving CAR-T therapy. The results should then be validated on a cohort and verified that they are reproducible in different contexts..

In France, this plasma RNA test is not validated and cannot currently guide therapeutic decisions. The use of CAR-T is always based on a specialized medical assessment, taking into account the disease, previous treatments and the general condition of the patient.

This research nevertheless opens an important perspective: tomorrow, a simple blood test could help doctors to better understand why immunotherapy works in certain patients and not in others. And perhaps, ultimately, to give more opportunities to those who need them most.